Kineticos Life Sciences

What Kineticos Life Sciences does

Kineticos Life Sciences is a privately held, founder-led life sciences investment and advisory firm headquartered in Raleigh, North Carolina. Founded by Shailesh Maingi in 2007 as a specialized management consulting firm, the company operates an integrated platform that combines dedicated venture and private equity funds (the Kineticos Disruptor Fund series, the Kineticos AMR Accelerator Fund I (KAMRA I), and the Kineticos Capital Partners Fund) with the Kineticos Foundry, an in-house company-creation studio that identifies, builds, and seeds new life sciences companies from R1 university research through in-licensing and spin-out execution. Kineticos has invested more than $75 million across 13 portfolio companies and grown to approximately $115 million in Assets Under Management as of December 31, 2024, with portfolio holdings spanning cell and gene therapy CDMOs (Kincell Bio, eXmoor, Arranta Bio), therapeutics (Amylyx, Inceptor Bio, EnteroBiotix, FastBack Bio), AMR-focused biotech (Kinvard Bio, Clarametyx, Endolytix, Orthobond), and medtech (neuro42, Promaxo, DIANT).

The firm serves biotech, biopharma, CDMO, diagnostics, and private equity clients through three consulting practice areas — Biopharmaceutical, Biopharmaceutical Services, and Diagnostics — covering strategy, business development and licensing, market access, M&A, and operational excellence. Revenue is generated via investment management fees and carried interest across the three funds, alongside fee-for-service, hybrid fee-for-service/success-based, and equity-based consulting engagements. Kineticos amplifies its brand through the Kineticos Research Institute (established 2016), the Biopharma CEO Confidence Index co-published with Ipsos Healthcare and Demy-Colton, and the Disruptor26 podcast, and has worked with over 6,000 firms globally across its consulting and investing activities.

Kineticos' technology and IP assets are concentrated in its proprietary Kineticos Foundry company-creation platform — combining R1 university sponsored research agreements, technology in-licensing, spin-out execution, and operator/venture capital — rather than a traditional software stack. Distribution is relationship-driven through a direct sales model anchored in the Raleigh headquarters and extended via co-investor and academic partnerships spanning the U.S. (RTP region), the UK (Scotland, through Eos Advisory and EnteroBiotix), and continental Europe (through INCATE).

Name

Kineticos Life Sciences

Legal name

Kineticos Life Sciences

Website

https://kineticos.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Raleigh

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Investment Management & Fund Returns: Manages three life-sciences investment vehicles — Kineticos Capital Partners Fund, Kineticos Disruptor Fund Series (I and II) and Kineticos AMR Accelerator Fund I (KAMRA I) — generating management fees, carried interest, and equity returns from portfolio investments across pharma services, biotech, and AMR.
2. Management & Strategy Consulting Services: Specialized life-sciences consulting practice organized by practice areas (Biopharmaceutical, Biopharmaceutical Services, Diagnostics) covering corporate strategy, business development & licensing, market access, innovation, operational excellence, M&A, and strategic sourcing for pharma, biotech, CROs, CMOs, diagnostics and PE clients.
3. Hybrid Fee-for-Service, Success-Based & Equity Engagements: Engages with companies via fee for service, hybrid fee for service/success based, and equity arrangements — providing consulting services in exchange for a mix of cash, success fees, and equity stakes.

Pricing tiers

Go-to-market motion4 records

Distribution channels3 records

Marketing channels8 records

Core offering

Kineticos Life Sciences is a privately held life sciences investment and advisory firm that deploys capital through specialized funds (Kineticos Capital Partners Fund, Kineticos Disruptor Fund I & II, and Kineticos AMR Accelerator Fund I) and operates the Kineticos Foundry to build and spin out new life sciences companies. The firm also delivers management consulting through three practice areas (Biopharmaceutical, Biopharmaceutical Services, and Diagnostics) and runs the Kineticos Research Institute, which publishes the Biopharma CEO Confidence Index and the Disruptor26 podcast.

Product overview

Kineticos Life Sciences is a life sciences-focused investment and advisory firm operating an integrated platform that combines dedicated venture and private equity funds (the Disruptor Fund series, the AMR Accelerator Fund (KAMRA), and the Capital Partners Fund) with the Kineticos Foundry company-creation studio, the Kineticos Research Institute thought tank, and three specialized consulting practices (Biopharmaceutical, Diagnostics, and Biopharmaceutical Services). Together, these offerings let Kineticos invest capital, build companies from inception through the Foundry, and provide strategic advisory services to therapeutic, diagnostic, and biopharma services clients, with thought leadership amplified through the Biopharma CEO Confidence Index and the Disruptor26 podcast.

Differentiator

Problem solved

Functional benefit

Brands

• Kineticos Capital Partners Fund: Investment fund powering the innovative life sciences ecosystem by investing in specialized pharma services, tools and equipment companies.
• Kineticos Disruptor Fund
• Kineticos Disruptor Fund II
• Kineticos AMR Accelerator Fund
• Kineticos Foundry

Products and services

• Kineticos Capital Partners Fund Private equity-style fund providing growth capital and strategic support to established life sciences companies, including outsourced pharma, tools, and equipment firms.
• Kineticos Disruptor Fund (Series I & II) Early-stage life sciences venture capital fund series investing in companies developing disruptive therapeutic, diagnostic, and biopharma service technologies.
• Kineticos AMR Accelerator Fund (KAMRA I) Specialized thematic venture fund backing therapeutic and diagnostic companies addressing drug-resistant infections and antimicrobial resistance.
• Kineticos Foundry Internal venture studio that identifies, builds, and seeds new life sciences companies (e.g., Kincell Bio, Kinvard Bio) from inception through initial financing, with focus areas including cell and gene therapy, protein degradation, AMR, AI, and contract services.
• Kineticos Biopharmaceutical Practice Consulting practice advising biopharmaceutical companies on strategy, business development & licensing, market access, innovation, operational excellence, M&A, and strategic sourcing.
• Kineticos Biopharmaceutical Services Practice Consulting practice focused on biopharma services and contract development/manufacturing organizations (CDMOs), supporting operational and growth strategies.
• Kineticos Diagnostics Practice Consulting practice advising diagnostic, life sciences tools, and precision medicine companies on growth strategy and commercialization.

Quantifiable outcome

• ~$115M of Assets Under Management as of December 31, 2024
• +7 more outcomes

Named customers5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered flagship academic partner, flagship regional partner, flagship amr partner, strategic clinical partner (inceptor bio), past consulting client, webinar co-host and research co-publisher.

• Harvard University Office of Technology Development / Myers Labflagship academic partnerStrategic or Co-development PartnerHarvard's Office of Technology Development licensed OPP lincosamide antibiotic technology developed in Professor Andy Myers' lab in the Department of Chemistry and Chemical Biology to Kinvard Bio, a Foundry company created by Kineticos AMR Accelerator Fund I.
• Eos Advisoryflagship regional partnerStrategic or Co-development PartnerIn February 2021, St Andrews-based Eos Advisory entered into a strategic partnership with Kineticos Disruptor Fund to co-invest in early-stage Scottish life sciences companies, targeting more than £10m over five years in oncology-focused firms.
• INCATE (INCubator for Antibacterial Therapies in Europe)flagship amr partnerStrategic or Co-development PartnerINCATE and Kineticos AMR Accelerator Fund I extended their strategic partnership in December 2024 (originally formed in 2023) to continue providing R&D and strategic support to early-stage ventures developing next-generation antimicrobial medicines; Kineticos plays an active role in selecting and supporting INCATE ventures.
• GRIT Bio / GRIT Biotechnologystrategic clinical partner (inceptor bio)Strategic or Co-development PartnerIn December 2024, Inceptor Bio (Kineticos portfolio company) and GRIT Bio announced a strategic partnership to advance IB-T101, an autologous CD70 CAR-T program; GRIT Bio received an exclusive license for IB-T101 in China and will oversee development, manufacturing, and commercialization, while Inceptor Bio is eligible for milestone payments and royalties.
• LSI Medience Corporationpast consulting clientImplementation/ SI/ Consulting PartnerIn July 2014, LSI Medience Corporation (Mitsubishi Chemical Holdings group) signed an agreement with Kineticos to identify opportunities for the Presepsin biomarker in sepsis management and demonstrate its utility in clinical trials.
• Cardinal Health Regulatory Scienceswebinar co-hostGTM or Marketing PartnerIn October 2016, Kineticos cohosted its first live webinar "Achieving Success in the Biosimilars Market" with Cardinal Health Regulatory Sciences, targeting biopharma C-suite, VPs, directors, and product managers.
• Ipsos Healthcareresearch co-publisherGTM or Marketing PartnerIpsos Healthcare partnered with Kineticos and Demy-Colton Life Science Advisors to publish the Biopharma CEO Confidence Index, a quarterly forward-looking indicator of biopharma C-suite sentiment.
• Demy-Colton Life Science Advisorsresearch co-publisherGTM or Marketing PartnerDemy-Colton Life Science Advisors co-publishes the Biopharma CEO Confidence Index with Kineticos and Ipsos Healthcare, and produces specialized investor and business conferences for the biopharmaceutical industry.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Longitude Capital: Healthcare-dedicated venture and growth equity firm with biopharma and medical-device verticals. Comparable fund size, sector focus, and stage (Seed to growth) as Kineticos' Disruptor and Capital Partners funds.
• Ampersand Capital Partners: Boston-based PE firm focused on life sciences and healthcare specialty pharma/services companies. Comparable mid-market thesis, portfolio company support model, and check sizes to Kineticos, especially in pharma services and tools.
• MVM Partners: Healthcare-specialized growth equity firm investing globally in pharma services, medical devices, and biotech. Co-invested with Kineticos in eXmoor's $35M Series A and is highly comparable as a mid-market life-sciences investor with similar check sizes.
• NewSpring Capital (NewSpring Healthcare): Lower-middle-market PE firm managing $3.5B+ across multiple strategies, including a dedicated healthcare/life-sciences strategy. Co-led Kincell Bio's $22M round with Kineticos in May 2025, making it the most operationally comparable US life-sciences PE peer.
• Telegraph Hill Partners: Life-sciences-focused growth equity and venture firm investing in pharma services, medical devices, and biotech. Closely comparable operating-partner-driven model and portfolio support approach.
• Pappas Capital: Research Triangle Park-based life-sciences venture and growth firm investing across therapeutics, devices, and pharma services. Direct geographic and thematic peer to Kineticos, also operating from the RTP ecosystem with a multi-fund platform.

Emerging players

• Atlas Venture: Early-stage biotech venture firm creating and seeding companies from academic research (a Foundry-style model). Conceptually comparable to Kineticos Foundry in company creation and oncology/neuroscience focus, but operates as a pure venture firm without consulting or pharma services coverage.

Broad incumbents

• Vivo Capital: Healthcare-focused investment firm with venture, growth, and public-equity strategies. Comparable in therapeutic focus (oncology, infectious disease) and ability to back companies across stages.
• Frazier Healthcare Partners: Long-established healthcare PE firm operating buyout and growth/public funds. Larger and broader than Kineticos but operates in the same life-sciences investment universe with comparable biopharma and pharma services theses.
• OrbiMed: Largest dedicated healthcare investment firm globally with venture, growth, and royalty/credit strategies. Comparable in biotech, pharma services, and AMR investing, but at much greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kineticos-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kineticos Life Sciences